Abstract: The present invention relates to compositions containing quinazolinones. More particularly, the present invention relates to a composition for the treatment of renal fibrosis. This composition includes, as an active ingredient, a quinazolinone derivative such as halofurginone, which is shown herein to slow or prevent progression of renal fibrosis in vivo thereby mitigating or preventing end-stage renal failure.

Abstract: An inhibitor of adhesion formation which can be used to prevent adhesions within the abdominal cavity, particularly following surgical intervention, trauma or inflammation in the area is disclosed. Specifically, the most preferred compound of the present invention, Halofuginone, can be used to prevent collagen deposition from occurring within the peritoneum after surgical intervention, thereby inhibiting adhesion formation. Halofuginone, and related compounds, are useful in the prevention and treatment of both inflammatory and surgically induced adhesions, and in the treatment of congenital adhesions.